Latest News & Features
Americas
Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz. 9 September 2021
Big Pharma
Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide. 9 September 2021
Medtech
Advanced Biologics has managed to convince the English High Court to expedite a patent infringement and validation suit it is embroiled in with German rival Med-El. 9 September 2021
Plant Varieties
International law firm Haynes Boone has launched the CBD Hemp Industry Group to advise businesses on the burgeoning cannabinoid market. 8 September 2021
Americas
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen. 7 September 2021
Americas
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market. 7 September 2021
Americas
In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis. 6 September 2021
Medtech
The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial. 2 September 2021
Americas
Belcher’s chief science officer deceived the US Patent and Trademark Office in order to obtain a patent, the US Court of Appeals for the Federal Circuit has ruled in a win for Pfizer’s subsidiary, Hospira. 2 September 2021
Generics
The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made. 2 September 2021